The fIrst·dose pharmacokinetics of FK506 was studied in nine orthotopic liver transplant patients receiving continuous intravenous infusion of O.lS mg/kg/dav. lvlultiple blood samples were obtained during the infusion and plasma FK506 concentrations were measured by enzyme-linked immunosorbent assay. The plasma clearance ranged from 0.47 to 5.B L/minute, and the half-life ranged from 4.5 hours to 33.1 hours. These results indicate the pharmacokinetics of FK506 to be highly variable between patients. FKS06 is extensively distributed outside the plasma compartment. FK506 is extensively metabolized in the body, with less than 1 %) of the administered dose being excreted in the urine as unchanged FK506. The large variability in FKS06 kinetics during the immediate post· operative period is attributed to the variability in the functional status of the liver in the transplant patients. Because of the long half-life of FKS06, it takes more than 45 hours to reach steady-state concentrations after continuous infusion. Based on the estimated kinetic parameters, it appears that a combination of a bolus or a rapid infusion of .02 mg/kg with a continuous infusion of o.os mg/kg/day will provide and maintain a concentration of more than 2 ng/mL from the beginning of the drug treatment.
F
K506 is a macrolide isolated from the fungus Streptomyces tsukubaensis. 1 It is nearly 100 times more potent than cyclosporine (CsA) in inhibiting lymphocyte proliferation in mixed lymphocyte cultures. 2 FKS06 has been shown to prevent or reverse the rejection of heart. liver, kidney. pancreas. lung, intestine, and skin grafts in mice. rats. dogs. monkeys, and baboons. 3 FKS06 has been in clinical use since March 1989 at the University of Pittsburgh. It was used initially for rescuing livers that have failed under conventional immunosuppression and later as the primary immunosuppressant for liver, kidney, and heart transplantation. 4 -6 Current results indicate that FKS06 provides better immunosuppression in liver and heart transplant recipients than does CsA. 4, [6] [7] [8] After transplantation, FK506 is administered intravenously as a continuous infusion at a dose of 0.15 mg/kg/day and then orally at a dose of 0.3 mg/kg/ day twice daily, when the patient can tolerate oral intake. Further dose alterations are normally made based on patient's liver function, episodes o'f rejection or toxicity, and trough plasma FK506 concentrations. The intravenous dosage form of FK506 is a 10-mg/mL FKS08 solution with polyethoxylated hydrogenated castor oil (HCO-60, a nonionic surfactant) and alcohol. This solution is diluted in 100 mL of 5% dextrose and infused at a rate of 4 mL/hour O\'er 24 hours. The pharmacokinetics of FKS06 has been previously studied in liver transplant patients who received their daily dose as a 2-or 4-hour infusion.g-ll The purpose of the curren t study was to characterize the pharmacokinetics of FKS06 in orthotopic liver transplant recipients receiving continuous intravenous administration of FKS06 during the immediate postoperative period and to compare actual steady-CONTINUOUS jj\lFUSION FK506 KINEnCS state FK506 concentrations with concentrations predicted based on the 24-hour kinetic study.
MATERIALS AND METHODS

Patients
Nine consecutive adult patients (8 men and 1 woman) who had undergone orthotopic liver transplantation received a continuous intravenous infusion ofFK506 (0.15 mg/kg/day) as their primary immunosuppressant 2 to 4 hours after surgery. FK506 was administered as a continuous intravenous infusion for a minimum of 3 to 6 days. They also received 20 mg of methyl prednisone during the first 24 hours. Patients' ages ranged from 24 to 64 years. and the patients weighed between 40 and 114 kg, with a mean of 71 kg. Written informed consents were obtained from all patients. and the study protocol was approved by the University of Pittsburgh Institutional Review Board for Biomedical Studies.
Specimen Collection
Multiple blood samples (3 mL) were drawn at 0, 15, 30,45 minutes, 1. 2, 3, 4, 5, 6. 8. 12, 16, and 24 hours after starting FK506 infusion from arterial lines into heparinized vacutainers. Blood samples were incubated at 37°C for 30 minutes. and plasma was separated by centrifugation at 37°C and frozen at -70 o e until analysis. Twenty-four-hour urine collections also were made, and aliquots of the samples were frozen for FK506 analysis.
Assay
FKs06 concentration in plasma separated at 37°e was measured by a monoclonal-antibody-based enzy-me-linked immunosorbent assay.1213-The coefficIent of variation of this assay is 19.8% at 0.4 ng/mL, 14% at 1.6 ng/mL. and 16% at 2.6 ng/mL.
Data Analysis
FK5~6 concentration-time data were analyzed by nonlInear curve fitting with MINSQ program (MINSQ. 1987) using a two-compartment model.
ARTIFICIAL INTELLIGENCE AND PHARMACOECONOMICS where Lam1 and Lam2 are the two exponents and the rest are as described by standard methods.14 Using the parameter estimates obtained from fitting the data (A. C. Lam1. Lam2. K 21 .) kinetic parameters (half-life. cleiuance. volume of distribution. and steady state plasma concentration C ss ) were calculated according to standard techniques. 14 In addition, the steady-state concentration that will be achieved on the infusion regimen was predicted for each patient based on the kinetic parameters (clearance) calculated from 24-hour plasma concentration-time data and the infusion rate (C ss = infusion rate/clearance) and compared with the actual steady-state concentrations measured 3 to 6 days after the ~tart of the infusion.
-
RESULTS
The characteristics of the patients who participated III the present study are summarized in Table I . The bilirubin and serum glutamic oxaloacetic transaminase and serum glutamic-pyruvic transaminase concentra.tions varied widely in these patients. A representatIve plasma concentration-time profile of FK506 in two patients (one with the lowest and one with the highest bilirubin) during continuous intravenous infusion is shown in Figure 1 . Table II Based on the pharmacokinetic par~meters calculated in each patient. the steady-state concentration that will be reached eventuallY"in these patients was calculated according to the following equation:
Steady state concentration = Infusion rate / Calculated Clearance Table III summarizes the biochemical profile and observed and predicted FK506 plasma concentrations on the last day of intravenous therapy. Reasonable agreement (less than 30% difference) was observed between the calculated and the actual C on days 3 to 6 in patients 4, 6,7, and 8. In patients 2s~nd
5, where the liver function improved based on bilirubin concentrations, the actual steady-state concentration on day 4 was less than what was predicted based on the first 24-hour kinetics. In patients 1 and 3. the predicted steady-state levels were lower than actual Cos reached on days 4 or 3, respectively. During this period, bilirubin concentrations increased in patient 3, indicating deterioration of liver function.
.. was not possible to determine the potential cross-reactivity of any FK506 metabolites with the antibody used in this assay. Preliminary studies, however, indicate that a fraction collected in HPLC (presumably a metabolite of FK506) does cross-react with the antibody used in the FK506 analysis (unpublished observation). In the absence of FK506 concentration measurement using a completely specific assay, the results of this study have to be interpreted with caution. The partitioning of FK506 between blood cells and plasma is temperature dependent. 15 To be physiologically meaningful. blood was separated at 37°C in this study . The overall beha vior of the drug in the body could be adequately described by a biexponential equation. The plasma concentrations attained in 24 hours with the infusion rate ofO.l5 mg/kg/day ranged between 2 and 7 ng/mL. The mean plasma clearance of FK506 was 1.76 L/minute and was variable between patients. Based on these data, one would classify FK506 as a high-clearance drug if the blood concentration of the drug were to be similar to the plasma concentration. Recent evidence, however, suggests that the drug is extensively distributed into red blood cells. with a blood-to-plasma ratio of nearly 12.15 This indicates that the clearance calculated from the blood data will be considerably small and the drug is actually a low clearance drug. In addition, it is possible that FK506 also may be metabolized extrahepatically; there is evidence of FK506 metabolism in rat small intestine. I6 There was a large variation in FK506 clearance between patients. The differences in the functional status of the liver between patients is expected to have contributed to the observed variation in the clearance of FK506. Factors such as cold ischemic dam- age. reperfusion injury. and accumulated endogenous inhibitors of drug metabolism also may have contributed to the observed variation in the clearance of FK506 during the immediate postoperative period. Lack of correlation between bilirubin levels and FK506 concentrations may be related to the fact that bilirubin concentrations may not reflect the functional status of the liver during the immediate postoperative period. The highest half-life and the smallest clearance values, however. were observed in a patient who had the highest serum bilirubin concentrations (>9 mg/ dL) during the entire first The large volume of distribution of FK506 suggests extensive distribution of the drug outside the plasma compartment. Recent studies have shown FK506 to bind preferentially tn erythrocytes with blood-toplasma ratios of 10 to 1 (Unpublished observation). Based on studies in animals,9 high concentrations of FK506 are expected in lungs. kidneys, heart. and spleen. Because of the large volume of distribution of FK506, the fact that FK506 is extensively metabolized in the liver. and that a large amount of FK506 remains outside the plasma compartment. for a given period of dialysis. a significant fraction of the body load of FK506 is not likely to be removed.
The mean half-life of FK506 is 15.5 hours. This indicates that after continuous infusion it will take at 610 • J Clin PharmacoI1993;33:606-611 least 45 hours to reach 90% of the steady-state levels. After a change in the dosing regimen. one has to wait for a minimum of 45 hours to attain a new steady_ state FKS06 plasma concentration. After continuous infusion of FKS06 at a dosage of O.lS mg/kg/ day. on average it would take nearly 10 hours to reach a plasma concentration of 2 ng/mL. Conversely. based on computer simulations, after two or four infusions this concentration is achieved in about 1 hour, but with a peak plasma concentration of6.7 and S.l ng/ mL at the end of the corresponding infusion times. One approach to achieving a concentration of about 2 ng/mL immediately after beginning of treatment and to maintaining it at this concentration is to use a small bolus dose or a rapid infusion over 1 hour of FKS06 (.02 mg/kg). The plasma concentration then can be maintained around 2 ng/mL by a continuous infusion at .05 mg/kg/day, started immediately ..
The pharmacokinetic parameters calculated after continuous infusion of FK506 are similar to the values reported after shorter infusion. lO · 11 It takes more than 4S hours to reach a new steady state after any change in the dosing regimen. It is necessary to closely monitor the FKS06 concentrations in patients, especially in the presence of abnormal liver function.
